Beyond CD19: Opportunities for future development of targeted immunotherapy in pediatric relapsed-refractory acute leukemia

Haneen eShalabi; Anne eAngiolillo; Terry J Fry

doi:10.3389/fped.2015.00080

Frontiers in Pediatrics (Oct 2015)

Beyond CD19: Opportunities for future development of targeted immunotherapy in pediatric relapsed-refractory acute leukemia

Haneen eShalabi,
Anne eAngiolillo,
Terry J Fry

Affiliations

Haneen eShalabi: Center for Cancer and Blood Disorders, Children's National Medical Center, Washington, D.C.
Anne eAngiolillo: Center for Cancer and Blood Disorders, Children's National Medical Center, Washington, D.C.
Terry J Fry: National Institutes of Health

DOI: https://doi.org/10.3389/fped.2015.00080
Journal volume & issue: Vol. 3

Abstract

Read online

Chimeric antigen receptor (CAR) T cell therapy has been used as a targeted approach in cancer therapy. Relapsed and refractory acute leukemia in pediatrics has been difficult to treat with conventional therapy due to dose limiting toxicities. With the recent success of CD 19 CAR in pediatric patients with B cell ALL, this mode of therapy has become a very attractive option for these patients with high risk disease. In this review, we will discuss current treatment paradigms of pediatric acute leukemia, and potential therapeutic targets for additional high risk populations, including T cell ALL, AML, and infant ALL.

Published in Frontiers in Pediatrics

ISSN: 2296-2360 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Pediatrics
Website: http://journal.frontiersin.org/journal/pediatrics

About the journal

Abstract

Keywords